Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Peng Liu; Liwei Zhao; Guido Kroemer; Oliver Kepp

doi:10.1080/2162402X.2024.2412874

Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

Peng Liu, Liwei Zhao, Guido Kroemer, Oliver Kepp

Résultats de recherche: Contribution à un journal › !!Comment/debate

Résumé

Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (T_R1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

langue originale	Anglais
Numéro d'article	2412874
journal	OncoImmunology
Volume	13
Numéro de publication	1
Les DOIs	https://doi.org/10.1080/2162402X.2024.2412874
état	Publié - 1 janv. 2024

Accès au document

10.1080/2162402X.2024.2412874

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{e47c8a683231407982d9e090aac98432,

title = "Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy",

abstract = "Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.",

keywords = "Immunotherapy, checkpoint inhibitor, immunogenic cell death, monoclonal antibody",

author = "Peng Liu and Liwei Zhao and Guido Kroemer and Oliver Kepp",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2024",

month = jan,

day = "1",

doi = "10.1080/2162402X.2024.2412874",

language = "English",

volume = "13",

journal = "OncoImmunology",

issn = "2162-4011",

number = "1",

}

TY - JOUR

T1 - Elimination of cDC1 cells by regulatory T cells jeopardizes cancer immunotherapy

AU - Liu, Peng

AU - Zhao, Liwei

AU - Kroemer, Guido

AU - Kepp, Oliver

PY - 2024/1/1

Y1 - 2024/1/1

N2 - Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

AB - Recent findings revealed that neoantigen-specific cytotoxic type 1 regulatory T (TR1) CD4 T cells can subvert cancer immunotherapy by killing type 1 conventional dendritic cells (cDC1s) that present tumor antigens bound to MHC class II. This underlines the importance of cDC1s for eliciting anticancer immunity but poses a novel clinical challenge.

KW - Immunotherapy

KW - checkpoint inhibitor

KW - immunogenic cell death

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=85205790443&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2024.2412874

DO - 10.1080/2162402X.2024.2412874

M3 - Comment/debate

C2 - 39376580

AN - SCOPUS:85205790443

SN - 2162-4011

VL - 13

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 2412874

ER -